Target Name: MKKS
NCBI ID: G8195
Review Report on MKKS Target / Biomarker Content of Review Report on MKKS Target / Biomarker
MKKS
Other Name(s): BBS6 | MKKS centrosomal shuttling protein, transcript variant 1 | KMS | McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin | MKKS variant 1 | MKKS_HUMAN | Bardet-Biedl syndrome 6 protein | McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin (isoform 1) | MKS | MKKS variant 2 | HMCS | MKKS centrosomal shuttling protein | Molecular chaperone MKKS | MKKS centrosomal shuttling protein, transcript variant 2 | alternative protein MKKS

MKKS: A Protein Target for Cancer, Autoimmune Disorders and Neurodegenerative Diseases

MKKS, also known as BBS6, is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a key regulator of the immune system and has been linked to a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

Recent studies have identified MKKS as a potential drug target for a number of different diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. This is because MKKS has been shown to play a role in the development and progression of these conditions, and may be able to be used to treat them.

One of the key reasons why MKKS has been identified as a potential drug target is because it is involved in the regulation of the immune system. The immune system is responsible for protecting the body against infection and disease, but sometimes it can become too active and cause problems, such as cancer or autoimmune disorders. MKKS has been shown to regulate the immune system and can be used to treat these conditions.

Another reason why MKKS has been identified as a potential drug target is because it has been shown to be involved in the development and progression of a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, studies have shown that people with certain genetic mutations, such as those associated with cancer, have lower levels of MKKS in their bodies. This suggests that MKKS may be a useful target for treating these conditions, as it can be used to increase the levels of MKKS in the body.

In addition to its potential as a drug target, MKKS has also been shown to have a number of potential benefits as a treatment. For example, studies have shown that MKKS can be used to treat a variety of conditions, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, some studies have shown that MKKS can be used to treat cancer by increasing the levels of MKKS in cancer cells, and that it may be effective in treating autoimmune disorders by reducing the levels of MKKS in the body.

Overall, MKKS is a protein that has been shown to play a number of important roles in the regulation of the immune system and the development and progression of a number of diseases. As a result, it has been identified as a potential drug target for a number of different conditions, including cancer, autoimmune disorders, and neurodegenerative diseases. Further research is needed to fully understand the role of MKKS as a drug target and to develop effective treatments for these conditions.

Protein Name: MKKS Centrosomal Shuttling Protein

Functions: Probable molecular chaperone that assists the folding of proteins upon ATP hydrolysis (PubMed:20080638). Plays a role in the assembly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the cilia (PubMed:20080638). May play a role in protein processing in limb, cardiac and reproductive system development. May play a role in cytokinesis (PubMed:28753627)

The "MKKS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MKKS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B